Skip Menu

Stroke Clinical Trials at OhioHealth

Pioneering Stroke Treatments and Technologies

WE are a nationwide leader in research through our active participation in stroke clinical trials.

Because of the high volume of stroke patients we treat, OhioHealth Neuroscience Center at Riverside Methodist Hospital is able to pioneer leading-edge treatments and technologies through active participation in clinical trials. 

Stroke Clinical Trials at OhioHealth – Riverside Methodist Hospital

Battelle Stroke Sleeve

Battelle Stroke Sleeve – Investigation of Electromyography (EMG) as an Evaluation Tool for Post-Stroke Rehabilitation

This is a feasibility study investigating an electromyography (EMG) and functional electrical stimulation (FES) sleeve in stroke patients receiving rehabilitation. To learn more, please reach out to OhioHealth Research Institute, Neuroscience Research at (614) 788-3879.


CO-MSTU – The Central Ohio Collaboration to Reduce Stroke Response Time Utilizing a Mobile Stroke Treatment Unit (CO – MSTU): Single – Center Outcomes

A prospective, observational study comparing MSTU transported patients to patients transported to the OhioHealth RMH ED by 911 EMS. To learn more, please reach out to OhioHealth Research Institute, Neuroscience Research at (614) 788-3879.


ENDOLOW – Endovascular Therapy for Low NIHSS Ischemic Strokes

This study will test the hypothesis that patients presenting within 8 hours of onset with cerebral ischemia in the setting of proximal large vessel occlusions (LVO) and low baseline NIHSS scores (0-5) will have better 90-day clinical outcomes (mRS distribution) with immediate mechanical thrombectomy (iMT) compared to initial medical management (iMM).       

Learn More at


FASTEST - Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial (FASTEST)

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. 

Learn More at


OCEANIC-STROKE - A Study to Learn More about Asundexian (Also Called BAY2433334) for Prevention of Ischemic Stroke

The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or temporary stroke-like symptoms when given in addition to standard antiplatelet therapy. A placebo is a treatment that looks like a medicine but does not have any medicine in it.

Learn More at


RHAPSODY-2 - Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke

The purpose of this study is to evaluate the efficacy and safety of intravenous doses of 3K3A-APC, a recombinant variant of human activated protein C (APC), in the treatment of acute ischemic stroke following treatment with thrombolysis, mechanical thrombectomy or both.

Learn More at


SUMMIT MAX – A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

The SUMMIT MAX study is a prospective, randomized, controlled, interventional clinical trial to evaluate the safety and effectiveness of the Route 92 Medical MonoPoint® Reperfusion System for aspiration thrombectomy in acute ischemic stroke patients.

Learn More at

Endovascular & Cardiac "Stroke Prevention" Trials


CREST 2 – Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) Protocol

A set of two multicenter randomized trials that run in parallel – CEA in addition to intensive medical management (IMM) vs. intensive medical management alone OR CAS + IMM vs. IMM alone.

Learn More at

CREST 2 Registry (C2R)

CREST 2 Registry (C2R)

A companion study to accompany CREST-2, this registry is for expansion of Medicare coverage for CAS to include procedures performed as part of C2R on symptomatic and asymptomatic patients beyond those categories covered under the 2005 CMS decision. Patients must either be excluded from or decline randomized trial CREST-2.

Learn More at